AIM ImmunoTech Inc. (AIM)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 150K 300K 450K FY16: 92K FY17: 437K FY18: 367K FY19: 140K FY20: 163K FY21: 135K FY22: 141K FY23: 202K FY24: 170K FY25: 88K FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-45M -30M -15M 0 15M 30M 45M FY16: -13.8M FY17: -11.4M FY18: -11.5M FY19: -12.4M FY20: -15.2M FY21: -18.8M FY22: -19.9M FY23: -31.9M FY24: -19.8M FY25: -11.7M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Net Income Annual

-30M -20M -10M 0 10M 20M 30M FY16: -7.5M FY17: -8.3M FY18: -9.8M FY19: -9.4M FY20: -14.4M FY21: -19.1M FY22: -19.4M FY23: -29M FY24: -17.3M FY25: -14M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Cost of Revenue Annual

0 600K 1.2M 1.8M FY15: 1.6M FY16: 1.1M FY17: 1.2M FY18: 884K FY19: 893K FY20: 806K FY21: 850K FY23: 42K FY24: 31K FY25: 128K FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY23 FY24 FY25

Operating Cash Flow Annual

-24M -16M -8M 0 8M 16M 24M FY16: -7.4M FY17: -7.9M FY18: -10.6M FY19: -9.1M FY20: -10.4M FY21: -14M FY22: -16.1M FY23: -21.3M FY24: -14.9M FY25: -11M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

-18M -12M -6M 0 6M 12M 18M FY14: -14.5M FY15: -16.3M FY16: -7.5M FY17: -8M FY18: -10.7M FY19: -9.1M FY20: -10.4M FY21: -14M FY22: -16.2M FY24: -14.9M FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY24

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 20M 40M 60M FY22: 48M FY23: 48.6M FY24: 560.2K FY25: 1.6M FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-21.00 -14.00 -7.00 0.00 7.00 14.00 21.00 Q3 '15: -1.26 Q4 '15: -0.37 Q1 '16: -0.45 Q2 '16: -0.49 Q3 '16: -0.44 Q4 '16: -0.33 Q1 '17: -0.34 Q2 '17: -0.36 Q3 '17: -0.27 Q4 '17: -0.29 Q1 '18: -0.25 Q2 '18: -2.55 Q3 '18: -5.38 Q4 '18: -6.64 Q1 '19: -9.48 Q2 '19: -8.17 Q3 '19: -6.43 Q4 '19: -2.58 Q1 '20: 0.11 Q2 '20: 1.07 Q3 '20: 2.12 Q4 '20: -0.50 Q1 '21: -0.36 Q2 '21: -0.37 Q3 '21: -0.37 Q4 '21: -0.40 Q1 '22: -0.40 Q2 '22: -0.38 Q3 '22: -0.43 Q4 '22: -0.40 Q1 '23: -0.40 Q2 '23: -0.40 Q3 '23: -0.43 Q4 '23: -0.60 Q1 '24: -0.64 Q2 '24: -3.54 Q3 '24: -9.38 Q4 '24: -19.04 Q1 '26: -3.24 Q2 '26: 0.01 Q3 '16 Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.